Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | YAP1 | P46937 | 1/20 | 0.50 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.50 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22571369 | 0.85 | SIRT2 (0.62) | RXFP1PTGS1MAPK8SIRT2TAS2R14 | |
| SCHEMBL9268782 | 0.85 | RXFP1 (0.78) | RXFP1SMN1; SMN2YAP1TEAD4TEAD2 | |
| SCHEMBL22556306 | 0.83 | RXFP1 (0.53) | RXFP1PTGS1MAPK8SMN1; SMN2SIRT2 | |
| SCHEMBL4245559 | 0.83 | MAPK8 (0.67) | RXFP1PTGS1MAPK8TEAD4TAS2R14 | |
| SCHEMBL25279533 | 0.82 | AKR1C3 (0.60) | RXFP1PTGS1MAPK8SMN1; SMN2YAP1 | |
| SCHEMBL22571350 | 0.81 | RXFP1 (0.51) | RXFP1PTGS1MAPK8SMN1; SMN2YAP1 | |
| SCHEMBL23701552 | 0.81 | RXFP1 (0.51) | RXFP1PTGS1MAPK8SMN1; SMN2SIRT2 | |
| SCHEMBL21053197 | 0.81 | MPO (0.55) | RXFP1PTGS1SMN1; SMN2TAS2R14AKR1C3 | |
| SCHEMBL4173936 | 0.80 | POLB (0.52) | RXFP1SIRT2NPC1RAB9AMEN1 | |
| SCHEMBL22556313 | 0.80 | AKR1C3 (0.46) | RXFP1PTGS1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116761795-A | Inhibitors of Transcription Enhancement Associated Domain (TEAD) and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2023049199-A1 | AZOLE COMPOUNDS | ZENO MANAGEMENT, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3793551-A1 | OXADIAZOLE COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| CN-111132673-A | Non-fused tricyclic compounds | 维瓦斯治疗公司 | 2020-05-08 | — | — | CN | disclosed |
| EP-3618818-A1 | NON-FUSED TRICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| WO-2018204532-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | RXFP1 3462/4885PTGS1 2350/4885MAPK8 1114/4885 |
| US-11186554-B2 | Non-fused tricyclic compounds | YAP1, MYC, TEAD2 | RXFP1 3462/4885PTGS1 2350/4885MAPK8 1114/4885 |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885PTGS1 2113/4885MAPK8 986/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885PTGS1 2113/4885MAPK8 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.